Logo image of MYGN

MYRIAD GENETICS INC (MYGN) Stock Fundamental Analysis

USA - NASDAQ:MYGN - US62855J1043 - Common Stock

7.84 USD
+0.07 (+0.9%)
Last: 9/22/2025, 8:48:05 PM
7.84 USD
0 (0%)
After Hours: 9/22/2025, 8:48:05 PM
Fundamental Rating

3

Overall MYGN gets a fundamental rating of 3 out of 10. We evaluated MYGN against 538 industry peers in the Biotechnology industry. While MYGN seems to be doing ok healthwise, there are quite some concerns on its profitability. MYGN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

MYGN had positive earnings in the past year.
In the past year MYGN has reported a negative cash flow from operations.
MYGN had negative earnings in each of the past 5 years.
In multiple years MYGN reported negative operating cash flow during the last 5 years.
MYGN Yearly Net Income VS EBIT VS OCF VS FCFMYGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

MYGN has a Return On Assets (-58.51%) which is in line with its industry peers.
MYGN has a Return On Equity (-102.09%) which is in line with its industry peers.
Industry RankSector Rank
ROA -58.51%
ROE -102.09%
ROIC N/A
ROA(3y)-14.88%
ROA(5y)-12.18%
ROE(3y)-21.45%
ROE(5y)-17.78%
ROIC(3y)N/A
ROIC(5y)N/A
MYGN Yearly ROA, ROE, ROICMYGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

With an excellent Gross Margin value of 70.44%, MYGN belongs to the best of the industry, outperforming 81.23% of the companies in the same industry.
In the last couple of years the Gross Margin of MYGN has declined.
The Profit Margin and Operating Margin are not available for MYGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 70.44%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5Y-1.76%
MYGN Yearly Profit, Operating, Gross MarginsMYGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

5

2. Health

2.1 Basic Checks

MYGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MYGN has more shares outstanding
The number of shares outstanding for MYGN has been increased compared to 5 years ago.
MYGN has a worse debt/assets ratio than last year.
MYGN Yearly Shares OutstandingMYGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
MYGN Yearly Total Debt VS Total AssetsMYGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

MYGN has an Altman-Z score of 0.26. This is a bad value and indicates that MYGN is not financially healthy and even has some risk of bankruptcy.
MYGN has a Altman-Z score of 0.26. This is in the better half of the industry: MYGN outperforms 60.78% of its industry peers.
There is no outstanding debt for MYGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.26
ROIC/WACCN/A
WACC9.77%
MYGN Yearly LT Debt VS Equity VS FCFMYGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

A Current Ratio of 1.42 indicates that MYGN should not have too much problems paying its short term obligations.
The Current ratio of MYGN (1.42) is worse than 81.04% of its industry peers.
MYGN has a Quick Ratio of 1.27. This is a normal value and indicates that MYGN is financially healthy and should not expect problems in meeting its short term obligations.
MYGN's Quick ratio of 1.27 is on the low side compared to the rest of the industry. MYGN is outperformed by 83.09% of its industry peers.
Industry RankSector Rank
Current Ratio 1.42
Quick Ratio 1.27
MYGN Yearly Current Assets VS Current LiabilitesMYGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 120.00% over the past year.
Measured over the past years, MYGN shows a very strong growth in Earnings Per Share. The EPS has been growing by 86.63% on average per year.
MYGN shows a small growth in Revenue. In the last year, the Revenue has grown by 3.83%.
MYGN shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.32% yearly.
EPS 1Y (TTM)120%
EPS 3Y86.63%
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)3.83%
Revenue growth 3Y6.64%
Revenue growth 5Y-0.32%
Sales Q2Q%0.76%

3.2 Future

Based on estimates for the next years, MYGN will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.77% on average per year.
The Revenue is expected to grow by 3.25% on average over the next years.
EPS Next Y-95.17%
EPS Next 2Y-4.6%
EPS Next 3Y25.5%
EPS Next 5Y15.77%
Revenue Next Year-1.94%
Revenue Next 2Y2.04%
Revenue Next 3Y3.48%
Revenue Next 5Y3.25%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MYGN Yearly Revenue VS EstimatesMYGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
MYGN Yearly EPS VS EstimatesMYGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 0.5 -0.5 1 1.5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 71.27 indicates a quite expensive valuation of MYGN.
Based on the Price/Earnings ratio, MYGN is valued cheaper than 91.08% of the companies in the same industry.
MYGN's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.41.
The Price/Forward Earnings ratio is 66.26, which means the current valuation is very expensive for MYGN.
MYGN's Price/Forward Earnings ratio is rather cheap when compared to the industry. MYGN is cheaper than 88.66% of the companies in the same industry.
MYGN is valuated expensively when we compare the Price/Forward Earnings ratio to 22.87, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 71.27
Fwd PE 66.26
MYGN Price Earnings VS Forward Price EarningsMYGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MYGN Per share dataMYGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

MYGN's earnings are expected to grow with 25.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.6%
EPS Next 3Y25.5%

More info and screens

0

5. Dividend

5.1 Amount

MYGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MYRIAD GENETICS INC

NASDAQ:MYGN (9/22/2025, 8:48:05 PM)

After market: 7.84 0 (0%)

7.84

+0.07 (+0.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners103.6%
Inst Owner Change-0.42%
Ins Owners2.55%
Ins Owner Change9.21%
Market Cap729.43M
Analysts53
Price Target7.31 (-6.76%)
Short Float %9.99%
Short Ratio4.99
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)338.77%
Min EPS beat(2)49.87%
Max EPS beat(2)627.66%
EPS beat(4)3
Avg EPS beat(4)219.97%
Min EPS beat(4)-2.9%
Max EPS beat(4)627.66%
EPS beat(8)7
Avg EPS beat(8)217.89%
EPS beat(12)9
Avg EPS beat(12)130.16%
EPS beat(16)13
Avg EPS beat(16)120.51%
Revenue beat(2)1
Avg Revenue beat(2)-0.38%
Min Revenue beat(2)-4.24%
Max Revenue beat(2)3.49%
Revenue beat(4)1
Avg Revenue beat(4)-0.99%
Min Revenue beat(4)-4.24%
Max Revenue beat(4)3.49%
Revenue beat(8)4
Avg Revenue beat(8)0.45%
Revenue beat(12)6
Avg Revenue beat(12)-0.31%
Revenue beat(16)8
Avg Revenue beat(16)-0.11%
PT rev (1m)-0.36%
PT rev (3m)-4.44%
EPS NQ rev (1m)49.41%
EPS NQ rev (3m)-186.9%
EPS NY rev (1m)0%
EPS NY rev (3m)272.27%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.62%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.49%
Valuation
Industry RankSector Rank
PE 71.27
Fwd PE 66.26
P/S 0.88
P/FCF N/A
P/OCF N/A
P/B 1.88
P/tB 4.39
EV/EBITDA N/A
EPS(TTM)0.11
EY1.4%
EPS(NY)0.12
Fwd EY1.51%
FCF(TTM)-0.51
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS8.95
BVpS4.17
TBVpS1.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -58.51%
ROE -102.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 70.44%
FCFM N/A
ROA(3y)-14.88%
ROA(5y)-12.18%
ROE(3y)-21.45%
ROE(5y)-17.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5Y-1.76%
F-Score5
Asset Turnover1.23
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 45.76%
Cap/Sales 3.24%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.42
Quick Ratio 1.27
Altman-Z 0.26
F-Score5
WACC9.77%
ROIC/WACCN/A
Cap/Depr(3y)84.29%
Cap/Depr(5y)59.14%
Cap/Sales(3y)6.65%
Cap/Sales(5y)4.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)120%
EPS 3Y86.63%
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-95.17%
EPS Next 2Y-4.6%
EPS Next 3Y25.5%
EPS Next 5Y15.77%
Revenue 1Y (TTM)3.83%
Revenue growth 3Y6.64%
Revenue growth 5Y-0.32%
Sales Q2Q%0.76%
Revenue Next Year-1.94%
Revenue Next 2Y2.04%
Revenue Next 3Y3.48%
Revenue Next 5Y3.25%
EBIT growth 1Y26.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.36%
EBIT Next 3Y46.98%
EBIT Next 5Y15.6%
FCF growth 1Y59.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y53.17%
OCF growth 3YN/A
OCF growth 5YN/A